This trial is for people with gynaecological cancers whose tumours are potentially treatable with endocrine treatment.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 2 Drug TrialEarly stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
- Registry listing
-
ERM Project ID
76231
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part?
Patients with gynaecological cancers with hormone receptor positive disease.
What is involved for you?
The purpose of this study is to test if oral treatment with letrozole (endocrine treatment), in combination with either alpelisib or ribociclib (medications that both work by blocking the growth of cancer cells) in gynaecological cancers will be more effective than letrozole alone in delaying cancer progression. Your tumour tissue will be tested for a certain type of genetic mutation, which may make your tumour more sensitive to certain types of treatment. The result of this genetic test will determine which of the experimental medicines you will receive. You will come into the clinic every 2-4 weeks for the first three months, during these visits you will have a physical exam, meet with the study nurse and doctor as well as having blood taken. You will also undergo standard tumour assessments via a scan. After the first three months, you will only be required to visit the clinic every three months for trial purposes.
